STAMFORD, Conn., Sept. 14, 2017 -- The Navigators Group, Inc. (NASDAQ:NAVG) announced today that Ciro M. DeFalco, Executive Vice President and Chief Financial Officer, and Vincent C. Tizzio, President, U.S. Insurance, will present at the Sidoti & Company Fall 2017 Conference on September 28th at 9:05 a.m. ET at the New York Marriott Marquis hotel in Times Square, New York City.
Participants can register for the live webcast at: http://www.investorcalendar.com/event/20236. A replay of the webcast will be available on this website approximately one hour after the presentation concludes and remain accessible for approximately 30 days.
The Navigators Group, Inc. is an international specialty insurance holding company with operations in the United States, the United Kingdom, Continental Europe and Asia.
Investors: Ciro M. DeFalco Executive Vice President and Chief Financial Officer 203-905-6343 Media: Courtney Oldrin 203-905-6531 [email protected]


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 



